Home / Themes / MedTech Short '25: Heavy China Exposure
MedTech Short '25: Heavy China Exposure (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 5 with notes · 6 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsEven though the BIOSECURE Act did not pass in April, the Trump 2.0 administration has signaled ongoing hostility toward China-linked biopharma operations. De fa
Thesis
Even though the BIOSECURE Act did not pass in April, the Trump 2.0 administration has signaled ongoing hostility toward China-linked biopharma operations. De facto pressure is being exerted through executive actions, federal agency contract constraints, and rhetorical/political overhangs. That's already driving anticipatory behavior—such as supply chain restructuring, domestic capex shifts, and RFP rerouting—hurting multinationals with large China exposure.
Bull case
Policy Pressure Despite Legislative Delay: Even without passage, agencies are quietly shifting procurement preferences away from companies with Chinese dependencies. Sentiment remains highly negative for bio multinationals.
Early Capex Shifts & Contract Losses: Anecdotal reports from smaller domestic players (TKNO, NOTV) indicate new client wins and RFP redirection from China-exposed competitors like DHR, IQV even in the absence of a formal mandate
China Still a Fundamental Drag: China remains a weak spot in life science earnings reports (e.g., WAT, DHR), as sentiment, pricing pressure, and trade disruptions persist amid broader U.S.-China decoupling dynamics
Bear case
BIOSECURE Act Failure Buys Time: With the act failing to pass, companies like DHR, IQV, and TECH get breathing room to adapt operations, lobby for exemptions, and avoid abrupt revenue loss or contract restrictions.
Stimulus & Stabilization in China and EU: Signs of stabilization in Chinese demand and fresh EU health system stimulus (including for diagnostics and biologics) could support revenue rebounds for multinationals with deep overseas exposure.
U.S. Cost Inflation & Supply Chain Complexity: Over-rotation into U.S.-only manufacturing could expose domestic players to capacity constraints and margin pressure, potentially making global, diversified firms like AMGN or NVO more competitive on cost and innovation.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| CRO/CDMO RFP Shifts from China to U.S. Providers | Quarterly | Measures dealflow and outsourcing shifts; a pivot away from IQV/DHR favors the short thesis. | Google_Sheets |
| Biopharma & Medtech Export Volume to U.S. (China & EU) | Monthly | Tracks trade rerouting and pressure from onshoring; falling volumes confirm thesis. | Google_Sheets |
| Company-Specific China Revenue and Commentary | Quarterly | Reveals demand softness, FX headwinds, and structural erosion in China exposure. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| AMGN_ce3d8cd2 | Including preparing for Miratide's launch. | 2026-01-01 | 2026-12-31 | Preparations and potential launch of Meritide, a novel therapy for obesity, type 2 diabetes, and related conditions. | Meritide is a key growth driver for Amgen. Its successful launch and market penetration would significantly impact Amgen's revenue and competitive position in the rapidly growing GLP-1 market. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_17b91ee0 | study completion expected in 2026. | 2026-07-01 | 2026-12-31 | Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease. | Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_f1821dd7 | We plan to launch TEPEZZA in additional markets in 2026 | 2026-01-01 | 2026-12-31 | Launch of TEPEZZA in additional international markets. | Expanding TEPEZZA's geographic reach will contribute to its global sales growth and further establish Amgen's presence in the thyroid eye disease market. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_a4f12076 | 2026 will be a year of disciplined data generation. From a number of exciting phase II and phase III programs that will pave the way for long-term growth at Amgen Inc. | 2026-01-01 | 2026-12-31 | Data generation and potential readouts from multiple ongoing Phase III clinical trials for Meritide in chronic weight management, ASCVD, heart failure, and sleep apnea. | Positive data from these late-stage trials could significantly enhance Amgen's competitive position in the rapidly expanding obesity and cardiometabolic markets, materially impacting future revenue guidance and valuation. Conversely, unfavorable outcomes would represent a significant setback. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| DHR_2e0838de | later this year | 2026-07-21 | 2026-12-31 | Completion of the pending acquisition of Masimo, subject to customary closing conditions and regulatory approvals. | This strategic acquisition is expected to be accretive to adjusted diluted net EPS in the first full year post-acquisition and deliver high single-digit return on invested capital by the fifth year, enhancing Danaher's acute care diagnostics strategy and offering significant synergies. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| DHR_d74bfae2 | Late July - August 2026 | 2026-07-20 | 2026-08-31 | Release of Q2 2026 biotech venture capital funding data. | Biotech funding levels are a primary lead indicator for lab CapEx budgets and early-stage R&D activity, directly impacting demand for analytical instrumentation and life science tools providers like Danaher. Management noted improved funnel activity driven by recovery in the funding environment. | Theme | 2026-04-21 | earnings_transcript | DHR (ticker) |
| DHR_ba441a9a | for the year | 2026-07-01 | 2026-12-31 | Further improvement in Life Sciences end markets, including accelerated growth in China and faster conversion of biotech funding into orders. | This would allow Danaher to achieve the higher end of its 2026 core revenue and adjusted EPS guidance, signaling stronger underlying demand and a more robust recovery in key market segments. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| ABBV_171a2b75 | Over the course of 2026 | 2026-04-26 | 2026-12-31 | Readout of Phase 3 data for both RINVOQ and lutekizumab in hidradenitis suppurativa. | Positive data could lead to new indications for RINVOQ and establish lutekizumab as a lead asset, significantly expanding AbbVie's immunology franchise. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_1bed7b86 | This year | 2026-04-26 | 2026-12-31 | Data from the Crohn's disease platform study evaluating SKYRIZI in combination with ABBV 3A2 and lutekizumab. | This data could demonstrate superior efficacy for patients, strengthening SKYRIZI's position and AbbVie's overall IBD portfolio, especially for patients who have already received SKYRIZI. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_dfdda14f | anticipate seeing efficacy results later this year | 2026-04-26 | 2026-12-31 | Efficacy results from dose escalation studies for ABBV 619, an in vivo CD19 CAR T platform for autoimmune diseases. | Positive results could signal a transformative new approach to autoimmune diseases, offering deep and durable remission and a significant long-term growth driver. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_5d3fb65c | initiating a phase three study this year | 2026-04-26 | 2026-12-31 | Initiation of a Phase 3 study for tmAbA in an all-comers population in combination with bevacizumab for colorectal cancer. | This advances tmAbA into late-stage development for a multibillion-dollar opportunity in CRC, bolstering AbbVie's oncology pipeline. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_800b4101 | an approval decision is anticipated in the third quarter for tevapadon in Parkinson's disease. | 2026-07-01 | 2026-09-30 | US commercial approval decision for tevapadon in Parkinson's disease. | Approval would add a new, potentially multibillion-dollar asset to AbbVie's neuroscience portfolio, offering a new treatment option for Parkinson's disease. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_47f622ef | data from both trials expected in the second half of this year. | 2026-07-01 | 2026-12-31 | Data readout from Phase 3 studies evaluating QLIPTA and UBRELVY for menstrual migraine prevention. | Positive data could lead to label expansions for these leading migraine products, addressing a distinct and difficult-to-treat subtype of migraine and further driving sales. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_ced91140 | by Q3 or so | 2026-07-01 | 2026-09-30 | Data from two additional cohorts of a Phase 2 study evaluating bradicilacin in major depressive disorder (MDD). | This data will inform the development strategy and Phase 3 plans, with bradicilacin having the potential to be a groundbreaking new treatment in depression due to its strong efficacy and short-acting profile. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_cba492a1 | an approval decision is expected this year. | 2026-04-26 | 2026-12-31 | US regulatory approval decision for Trenebody, a rapid-onset short-acting toxin for aesthetics. | Approval and subsequent launch could stimulate the aesthetics market by attracting new patients and ultimately accrue to Botox share, increasing overall revenue. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| IQV_56694b67 | August 2026 | 2026-08-01 | 2026-08-31 | Enforcement of the EU AI Act's high-risk requirements. | Given IQVIA's extensive integration of AI into its solutions and its proprietary data foundation, the enforcement of these regulations could increase compliance burdens and costs for its AI-driven data services in Europe, potentially impacting operational flexibility and margins. | Theme | 2026-05-05 | earnings_transcript | IQV (ticker) |
| AMGN_2e8df87c | August 19, 2026 (estimated) | 2026-08-19 | 2026-08-19 | Completion of the Phase III HZNP-DAZ-301 study for Dazodalibep in Sjogren's syndrome with moderate-to-severe systemic disease activity. | This is a key data collection milestone for a potential new treatment for Sjogren's disease, a condition with high unmet medical need, and could lead to future regulatory filings and market expansion. | Ticker | 2026-04-30 | earnings_transcript | AMGN (ticker) |
| AMGN_b978ca77 | 2026-09-07 (Estimated) | 2026-09-07 | 2026-09-07 | Initiation of the Phase 2/3 study (NCT07598825) for UPLIZNA (inebilizumab) in participants with autoimmune hepatitis. | This initiation represents the expansion of UPLIZNA into a new, significant autoimmune indication, broadening its potential therapeutic reach and future revenue streams. | Ticker | 2026-04-30 | earnings_transcript | AMGN (ticker) |
| DHR_f825acc1 | by the end of the year | 2026-10-01 | 2026-12-31 | Abatement of policy headwinds in China diagnostics, normalization of respiratory revenue, and improved year-over-year comparisons in Life Sciences. | The resolution of these headwinds is projected to drive an acceleration in Danaher's core revenue growth, enabling the company to achieve mid-single-digit core growth by the end of Q4 2026. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| DHR_0a68fb32 | Q4 | 2026-10-01 | 2026-12-31 | A stronger-than-typical seasonal respiratory infection rate in the fourth quarter of 2026. | A robust respiratory season would contribute to Danaher's goal of returning to an endemic $1.8 billion respiratory revenue rate and help achieve the higher end of its full-year 2026 guidance. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| ABBV_c5da1469 | anticipated in the fourth quarter | 2026-10-01 | 2026-12-31 | US regulatory approval decision for RINVOQ in nonsegmental vitiligo. | Approval would expand RINVOQ's market to a new systemic indication, potentially adding to its multi-billion dollar sales trajectory. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| IQV_2593c7c7 | December 1-2, 2026 | 2026-12-01 | 2026-12-02 | COG: CRO Summit in North Carolina, focusing on AI integration and clinical trial innovation. | This summit will highlight cutting-edge topics such as AI integration and clinical trial innovation. Key announcements or presentations could reveal new opportunities and competitive advantages for CROs like IQVIA, leveraging advanced technologies and operational efficiencies. | Theme | 2026-05-05 | earnings_transcript | IQV (ticker) |